Male hormonal contraception: A double-blind, placebo-controlled study

Journal of Clinical Endocrinology and Metabolism

Volumn 93, Issue 7, 2008, Pages 2572-2580

  Mommers, Ellen ^a   Kersemaekers, Wendy M ^a   Elliesen, Jörg ^b   Kepers, Marc ^a   Apter, Dan ^c   Behre, Hermann M ^d   Beynon, Jennifer ^e   Bouloux, Pierre M ^f   Costantino, Antonietta ^g   Gerbershagen, Hans Peter ^d   Grønlund, Lars ^h   Heger Mahn, Doris ⁱ   Huhtaniemi, Ilpo ^j   Koldewijn, Evert L ^k   Lange, Corinna ⁱ   Lindenberg, Svend ^h   Meriggiola, M Cristina ^g   Meuleman, Eric ^l   Mulders, Peter F A ^l   Nieschlag, Eberhard ^m   Perheentupa, Antti ⁿ   Solomon, Andrew ^f   Väisälä, Leena ^c   Wu, Frederick C ^e   Zitzmann, Michael ^m   more..

^a NV ORGANON   (Netherlands)

^b BAYER PHARMA AG   (Germany)

^c Vaestoliitto   (Finland)

^d MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

^f ROYAL FREE HOSPITAL   (United Kingdom)

^g UNIVERSITY OF BOLOGNA   (Italy)

^h Nordica Fertility Clinic and Research Center   (Denmark)

ⁱ Dinox GmbH   (Germany)

^j IMPERIAL COLLEGE LONDON   (United Kingdom)

^k CATHARINA HOSPITAL   (Netherlands)

^l RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^m UNIVERSITY OF MÜNSTER   (Germany)

ⁿ UNIVERSITY OF TURKU   (Finland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ETONOGESTREL; PLACEBO; TESTOSTERONE UNDECANOATE;

ACNE; ADULT; ALOPECIA; ARTICLE; CALCULUS PROSTATE; CARTILAGE INJURY; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAPHRAGM HERNIA; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPILEPSY; ERECTILE DYSFUNCTION; ESOPHAGITIS; FATIGUE; FOLLOW UP; GYNECOMASTIA; HEART DISEASE; HEART MUSCLE ISCHEMIA; HEART PAPILLARY MUSCLE HYPERTROPHY; HORMONAL CONTRACEPTION; HUMAN; INJECTION SITE REACTION; JOINT INJURY; KIDNEY DISEASE; LIBIDO; LIBIDO DISORDER; LIGAMENT INJURY; MALE; MOOD CHANGE; MULTICENTER STUDY; MUSCLE HYPERTROPHY; NIGHT SWEAT; NORMAL HUMAN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE DISEASE; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SPERM; SPERMATOGENESIS; SUICIDE ATTEMPT; SWEATING; TREATMENT DURATION; WEIGHT GAIN;

EID: 47549091001     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2008-0265     Document Type: Article

References (25)

1. Martin CW, Anderson RA, Cheng L, Ho PC, Van der Spuy Z, Smith KB, Glasier AF, Everington D, Baird DT 2000 Potential impact of hormonal male contraception: cross-cultural implications for development of novel preparations. Hum Reprod 15:637-645
2. Heinemann K, Saad F, Wiesemes M, White S, Heinemann L 2005 Attitudes toward male fertility control: results of a multinational survey on four continents. Hum Reprod 20:549-556
3. WHO task force on methods for the regulation of male fertility 1990 Contraceptive efficacy of testosterone-induced azoospermia in normal men. Lancet 336:955-959
4. WHOTask Force on Methods for the Regulation of Male Fertility 1996 Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men. Fertil Steril 65:821-829
5. Wenk M, Nieschlag E 2006 Male contraception: a realistic option? Eur J Contracept Reprod Health Care 11:69-80
6. Matthiesson KL, McLachlan RI 2006 Male hormonal contraception: concept proven, product in sight? Hum Reprod Update 12:463-482
7. Grimes DA, Gallo MF, Grigorieva V, Nanda K, Schulz KF 2005 Steroid hormones for contraception in men: systematic review of randomized controlled trials. Contraception 71:89-94
8. Hay CJ, Brady BM, Zitzmann M, Osmanagaoglu K, Pollanen P, Apter D, Wu FCW, Anderson RA, Nieschlag E, Devroey P, Huhtaniemi I, Kersemaekers WM 2005 A multicenter phase II-b study of a novel combination of intramuscular androgen (testosterone decanoate) and oral progestogen (etonogestrel) for male hormonal contraception. J Clin Endocrinol Metab 90:2042-2049
9. Brady BM, Amory JK, Perheentupa A, Zitzmann M, Hay CJ, Apter D, Anderson RA, Bremner WJ, Pollanen P, Nieschlag E, Wu FCW, Kersemaekers WM 2006 A multicentre study investigating subcutaneous etonogestrel implants with injectable testosterone decanoate as a potential long-acting male contraceptive. Hum Reprod 21:285-294
10. Von Eckardstein S, Nieschlag E 2002 Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a phase II study. J Androl 23:419-425
11. Morales A, Nieschlag E, Schubert M, Yassin AA, Zitzmann M, Oettel M 2006 Clinical experience with the new long-acting injectable testosterone undecanoate. Aging Male 9:221-227
12. WHO 1999 Laboratory manual for the examination of human semen and sperm-cervical mucus interaction. 4th ed. Cambridge, UK: Cambridge University Press
13. Jonckheere J, Callewaert N, Grootenhuis AJ, Kersemaekers WM, Cooper TG 2005 Feasibility study for the centralized measurement of sperm concentration. Int J Androl 28:311-315
14. Cooper TG, Hellenkemper B, Jonckheere J, Callewaert N, Grootenhuis AJ, Kersemaekers WM, Leung A, Wang C 2006 Azoospermia: virtual reality or possible to quantify? J Androl 27:483-490
15. Turner L, Conway AJ, Jimenez M, Liu PY, Forbes E, McLachlan RI, Handelsman DJ 2003 Contraceptive efficacy of a depot progestin and androgen combination in men. J Clin Endocrinol Metab 88:4659-4667
16. Kamischke A, Heuermann T, Krüger K, Von Eckardstein S, Schellschmidt I, Rübig A, Nieschlag E 2002 An effective hormonal male contraceptive using testosterone undecanoate with oral or injectable norethisterone preparations. J Clin Endocrinol Metab 87:530-539
17. Meriggiola MC, Constantino A, Saad F, D'Emidio L, Morselli Labate AM, Bertaccini A, Bremner WJ, Rudolph I, Ernst M, Kirsch B, Martorana G, Pelusi G 2005 Norethisterone enanthate plus testosterone undecanoate for male contraception: effects of various injection intervals on spermatogenesis, reproductive hormones, testis, and prostate. J Clin Endocrinol Metab 90:2005-2014
18. Gu YQ, Wang XH, Xu D, Peng L, Cheng L-F, Huang M-K, Huang Z-J, Zhang G-Y 2003 A multicenter contraceptive efficacy study of injectable testosterone undecanoate in healthy Chinese men. J Clin Endocrinol Metab 88:562-568
19. McLachlan RI, Robertson DM, Pruysers E, Ugoni A, Matsumoto AM, Anawalt BD, Bremner WJ, Meriggiola C 2004 Relationship between serum gonadotropins and spermatogenic suppression in men undergoing steroidal contraceptive treatment. J Clin Endocrinol Metab 89:142-149
20. Anderson RA, Kinniburgh D, Baird DT 2002 Suppression of spermatogenesis by etonogestrel implants with depot testosterone: potential for long-acting male contraception. J Clin Endocrinol Metab 87:3640-3649
21. Wu FCW, Balasubramanian R, Mulders TMT, Coelingh-Bennink HJT 1999 Oral progestogen combined with testosterone as a potential male contraceptive: additive effects between desogestrel and testosterone enanthate in suppression of spermatogenesis, pituitary-testicular axis, and lipid metabolism. J Clin Endocrinol Metab 84:112-122
22. Liu PY, Swerdloff RS, Christenson PD, Handelsman DJ, Wang C 2006 Rate, extent, and modifiers of spermatogenic recovery after hormonal male contraception: an integrated analysis. Lancet 367:1412-1420
23. Tenth Summit meeting consensus 2007 Recommendations for regulatory approval for hormonal male contraception. Int J Androl 30:63-64
24. Hair WM, Kitteridge K, O'Connor DB, Wu FC 2001 A novel male contraceptive pill-patch combination: oral desogestrel and transdermal testosterone in the suppression of spermatogenesis in normal men. J Clin Endocrinol Metab 86:5201-5209
25. Gonzalo IT, Swerdloff RS, Nelson AL, Clevenger B, Garcia R, Berman N, Wang C 2002 Levonorgestrel implants (Norplant II) for male contraception clinical trials: combination with transdermal and injectable testosterone. J Clin Endocrinol Metab 87:3562-3572